Search
Showing results for "aboriginal respiratory"
Lung inflammation and impaired alveolarization precede bronchopulmonary dysplasia (BPD). Glucocorticoids are anti-inflammatory and reduce ventilator requirements in preterm infants. However, high-dose glucocorticoids inhibit alveolarization. The effect of glucocorticoids on lung function and structure in preterm newborns exposed to antenatal inflammation is unknown. We hypothesise that postnatal low-dose dexamethasone reduces ventilator requirements, prevents inflammation and BPD-like lung pathology, following antenatal inflammation.
Perinatal inflammation increases the risk for bronchopulmonary dysplasia in preterm neonates, but the underlying pathophysiological mechanisms remain largely unknown. Given their anti-inflammatory and regenerative capacity, multipotent adult progenitor cells (MAPC) are a promising cell-based therapy to prevent and/or treat the negative pulmonary consequences of perinatal inflammation in the preterm neonate.
We invite all Supply Partners to make us their Corporate Social Responsibility (CSR) partner in Western Australia.
Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Kefyalew Alene BSc, MPH, PhD Head, Geospatial and Tuberculosis 0404705064 Kefyalew.alene@thekids.org.au Honorary Research Fellow Dr Kefyalew Alene
The Kids Discovery Centre is offering a brand-new program of fun and engaging workshops for kids during the Term 3 School Holidays.
Elastase exocytosis by airway neutrophils is associated with early lung damage in children with cystic fibrosis Abstact Rationale: Neutrophils are
Bronchiectasis is a condition where the lungs become damaged and prone to infections.
We compared information on the life expectancy of Dr Rett's original group in 1966 with information in the Australian Rett Syndrome Database.
Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au The Vaccine Trials Group